NCT00622336 - A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma | Biotech Hunter

Enrollment

330

Participants

Timeline

Start Date

April 1, 2003

Primary Completion Date

November 25, 2013

Study Completion Date

November 25, 2013

Conditions

Multiple Myeloma

Interventions

DRUG

CC-5013

Oral 25mg daily on Days 1-21 every 28 days.

DRUG

Lenalidomide

Oral Lenalidomide 25mg daily on Days 1-21 every 28 days.

Trial Locations (7)

Kharkov Postgraduate Medical Academy Kharkov Regional Clinical, Kharkiv

Odessa Regional Clinical Hospital, Odesa

Republican Clinical Hospital #1, Izhevsk

Samara Regional Clinical Hospital, Samara

Nizhny Novgorod Clinical Hospital n.a.Semashko, Nizhny Novgorod

Novosibirsk State Regional Clinical, Novosibirsk

Institute of Hematology and Transfusiology of the UAMS Department of blood diseases, Kiev